www.aad.org/media/stats/conditions/skin-conditions-by-the-numbers. Accessed March 15, 2021. 4. Hebert A, et al JAMA Dermatol. 2020;156(6):621-630 5. Eichenfield, L., et al. J Am Acad Dermatol. 2020 Aug;83(2):477-485. doi: 10.1016/j.jaad.2020.04.087. Epub 2020 Apr

26. 6. Rosette C, et al. J Drugs Dermatol. 2019; 18(5):412-418. https://www.ncbi.nlm.nih.gov/pubmed/31141847

Some of the information contained in this press release may contain forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cassiopea has no obligation to publicly update or revise any forward-looking statements.

Press Release (PDF) ----------------------------------------------------------------------------------------------------------------------- End of ad hoc announcement ----------------------------------------------------------------------------------------------------------------------- 


Language:     English 
Company:      Cassiopea S.p.A. 
              Via Cristoforo Colombo 1 
              20045 Lainate 
              Switzerland 
E-mail:       info@cassiopea.com 
Internet:     https://www.cassiopea.com/ 
ISIN:         IT0005108359 
Listed:       SIX Swiss Exchange 
EQS News ID:  1178292 
 
End of Announcement EQS Group News Service 
=------------

1178292 25-March-2021 CET/CEST

(END) Dow Jones Newswires

March 25, 2021 02:03 ET (06:03 GMT)